02:06 PM EDT, 05/16/2025 (MT Newswires) -- Acadia Pharmaceuticals ( ACAD ) said Friday a US district court ruled in its favor in formulation patent litigation against Aurobindo Pharma and other abbreviated new drug application filers.

The lawsuit involved Acadia's '721 formulation patent for Nuplazid, its treatment for Parkinson's disease psychosis.

The US District Court for the District of Delaware sided with Acadia on both infringement and validity arguments, the company said.

Shares of Acadia Pharmaceuticals ( ACAD ) were up more than 25% in recent trading.

Price: 22.09, Change: +4.49, Percent Change: +25.51